Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 7/20 | 0.65 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.63 |
| ▸ | CDK2 | P24941 | 9/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | GSK3A | P49840 | 2/20 | 0.63 |
| ▸ | GSK3B | P49841 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398263 | 0.94 | CDK5 (0.72) | CDK5CDK5R1NPC1MEN1KMT2A | |
| SCHEMBL20142073 | 0.89 | CCNA2 (0.68) | CDK5CDK5R1NPC1MEN1KMT2A | |
| SCHEMBL4395265 | 0.88 | GSK3A (0.73) | CDK5CDK5R1NPC1MEN1KMT2A | |
| SCHEMBL20142403 | 0.88 | CCNA2 (0.78) | CDK5CDK5R1NPC1MEN1KMT2A | |
| SCHEMBL20142148 | 0.88 | GSK3A (0.73) | CDK5CDK5R1NPC1MEN1KMT2A | |
| SCHEMBL20142846 | 0.88 | CCNA2 (0.78) | CDK5CDK5R1NPC1MEN1KMT2A | |
| SCHEMBL20142259 | 0.88 | GSK3A (0.73) | CDK5CDK5R1NPC1MEN1KMT2A | |
| SCHEMBL20142192 | 0.88 | CCNA2 (0.78) | CDK5CDK5R1NPC1MEN1KMT2A | |
| SCHEMBL7757586 | 0.88 | CCNA2 (0.82) | CDK5CDK5R1NPC1MEN1KMT2A | |
| SCHEMBL25609810 | 0.88 | CCNA2 (0.82) | CDK5CDK5R1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089902-A1 | DIAMINOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2018-05-17 | — | — | WO | claimed |
| WO-2018089902-A1 | DIAMINOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2018-05-17 | — | — | WO | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | CDK5 1039/4885CDK5R1 1256/4885NPC1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.